Key PointsWhen evaluating the two companies based strictly on the most recent quarterly data, Eli Lilly currently shows a higher overall revenue base and a demonstrably faster upward sales trajectory than Bristol Myers Squibb.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.